G6PD and pancreatic ductal adenocarcinoma: Complementing these findings, metabolomics-based profiling of pancreatic ductal adenocarcinoma organoids delineates glucomet-PDAC (high glucose metabolism) and lipomet-PDAC (enhanced lipid metabolism); the glucomet subtype is more chemoresistant and portends worse prognosis, driven by a GLUT1-aldolase B (ALDOB)-glucose-6-phosphate dehydrogenase (G6PD) axis that reprograms glucose metabolism [281].